Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
Masquelier B, Assoumou KL, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin AG, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-Vézinet F, Costagliola D; ANRS Resistance Study Group. Masquelier B, et al. J Antimicrob Chemother. 2008 Jun;61(6):1362-8. doi: 10.1093/jac/dkn127. Epub 2008 Apr 4. J Antimicrob Chemother. 2008. PMID: 18390885
Clinically relevant interpretation of genotype for resistance to abacavir.
Brun-Vézinet F, Descamps D, Ruffault A, Masquelier B, Calvez V, Peytavin G, Telles F, Morand-Joubert L, Meynard JL, Vray M, Costagliola D; Narval (ANRS 088) Study group. Brun-Vézinet F, et al. AIDS. 2003 Aug 15;17(12):1795-802. doi: 10.1097/00002030-200308150-00008. AIDS. 2003. PMID: 12891065
Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).
Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group. Vray M, et al. Antivir Ther. 2003 Oct;8(5):427-34. doi: 10.1177/135965350300800510. Antivir Ther. 2003. PMID: 14640390 Clinical Trial.
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
Marcelin AG, Cohen-Codar I, King MS, Colson P, Guillevic E, Descamps D, Lamotte C, Schneider V, Ritter J, Segondy M, Peigue-Lafeuille H, Morand-Joubert L, Schmuck A, Ruffault A, Palmer P, Chaix ML, Mackiewicz V, Brodard V, Izopet J, Cottalorda J, Kohli E, Chauvin JP, Kempf DJ, Peytavin G, Calvez V. Marcelin AG, et al. Antimicrob Agents Chemother. 2005 May;49(5):1720-6. doi: 10.1128/AAC.49.5.1720-1726.2005. Antimicrob Agents Chemother. 2005. PMID: 15855487 Free PMC article. Clinical Trial.
168 results